Comparative Pharmacology
Head-to-head clinical analysis: FERAHEME versus NEXESTA FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERAHEME versus NEXESTA FE.
FERAHEME vs NEXESTA FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferumoxytol is a superparamagnetic iron oxide nanoparticle coated with a semisynthetic carbohydrate shell. It serves as a source of iron for hemoglobin synthesis and replenishes iron stores. The iron core is processed intracellularly to release iron, which is then incorporated into hemoglobin or stored as ferritin. The carbohydrate shell is metabolized and eliminated.
Norepinephrine-dopamine reuptake inhibitor (NDRI); weakly inhibits serotonin reuptake. Also releases norepinephrine from presynaptic neurons.
510 mg intravenously once, followed by a second 510 mg dose 3 to 8 days later, not exceeding 1020 mg per course.
One tablet (containing 1 mg norethindrone acetate and 1.5 mg ethinyl estradiol) orally once daily for 28-day cycle.
None Documented
None Documented
Terminal half-life of ferumoxytol (iron core) is approximately 14-21 hours; for the intact nanoparticle (carbohydrate shell), half-life is about 15 hours. Clinically, iron is continuously released and incorporated, extending effects beyond half-life.
Terminal half-life: 4-6 hours; clinical context: dosing every 4-6 hours for pain.
Renal: minimal (<1% as intact drug); primarily degraded endogenously with iron incorporated into hemoglobin; fecal/biliary elimination of unabsorbed iron is negligible.
Renal: 20-30% unchanged; fecal/biliary: 70-80% as metabolites.
Category C
Category C
Iron Supplement
Iron Supplement